Jade Biosciences, Inc. JBIO
14.42
(0.31)
(2.10%)
as of 25 Sep
- Market cap
- $936.8M
- P/E
- 0.0×
Follow JBIO
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
21.09 | 5.81 | 7.04 | 16.90 | 68.37 | 2.64 | 5.35 | — |
Net Debt/EBITDA |
2.94 | (1.08) | 1.45 | 2.38 | 7.26 | 0.51 | 0.30 | — |
Debt/Assets |
0.00% | 147.80% | 0.00% | 0.52% | 0.22% | 0.00% | 71.14% | 0.00% |
Debt/Equity |
0.00 | (2.30) | 0.00 | 0.01 | 0.00 | 0.00 | (0.69) | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.95 | 0.48 | 0.75 | 0.76 | 1.19 | 0.82 | 0.84 | — |
Capex/Depreciation |
0.26 | 0.00 | 0.05 | 0.23 | (5.84) | 0.00 | — | — |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| (70.09%) | (149.96%) | (63.95%) | (34.44%) | (28.87%) | 113.16% | 39.21% | — | |
| (47.39%) | (46.93%) | (57.49%) | (33.16%) | (25.50%) | (233.59%) | (189.53%) | — | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | (265.23%) | 0.00% | 0.00% | — |
Return on Tangible Assets |
(30.12%) | (81.47%) | (70.66%) | (41.56%) | (13.35%) | (326.79%) | (116.56%) | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — |
Free Cash Flow per Share |
(3.03) | (7.17) | (75.84) | (56.37) | (78.71) | (1,138.99) | (403.04) | — |
Cash per Share |
10.72 | 21.99 | 163.14 | 185.26 | 477.67 | 662.75 | 509.28 | — |
Shareholders Equity per Share |
10.60 | (14.83) | 145.84 | 181.71 | 492.06 | (1,933.91) | (527.97) | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
10.60 | (14.83) | 145.84 | 181.71 | 492.06 | (1,933.91) | (527.97) | — |
Free Cash Flow |
(94.88) | (22.61) | (56.92) | (39.32) | (27.58) | (7.86) | (2.78) | — |
Working Capital |
332.28 | 57.66 | 106.60 | 123.71 | 171.78 | 2.90 | 2.86 | — |
Capital Expenditures |
(0.20) | — | (0.14) | (0.19) | (0.18) | — | — | — |
Net Current Asset Value |
331.55 | (49.94) | 106.27 | 122.94 | 171.39 | (13.38) | (3.64) | — |
| Other line items | ||||||||
Quick Ratio |
20.33 | 5.78 | 6.94 | 16.61 | 65.64 | 2.58 | 5.35 | — |
Depreciation/Fixed assets |
(4.46) | (327.67) | (10.28) | (3.48) | 0.17 | 0.03 | — | — |
Cash ROIC |
(14.19%) | (17.38%) | (24.61%) | (15.34%) | (8.11%) | 90.05% | (117.29%) | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(3.02) | (7.17) | (75.65) | (56.09) | (78.19) | (1,138.99) | (403.04) | — |
Capex per Share |
(0.01) | 0.00 | (0.19) | (0.28) | (0.52) | 0.00 | 0.00 | — |
Average Payables |
1.72 | 1.84 | 2.49 | 1.89 | 0.91 | 0.58 | 0.58 | — |
Average Assets |
211.29 | 100.11 | 131.36 | 155.33 | 90.04 | 4.11 | 1.76 | — |
Average Common Equity |
142.86 | 31.33 | 118.10 | 149.58 | 79.54 | (8.49) | (8.49) | — |
Capex to Sales |
0.00 | — | 0.00 | 0.00 | 0.00 | — | — | — |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Columns are period end dates